Related Experiment Video

Updated: Dec 28, 2025

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.6K

Myotubularin-related protein 14 suppresses cardiac hypertrophy by inhibiting Akt

Jie-Lei Zhang1, Dian-Hong Zhang2, Ya-Peng Li2

  • 1Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450052, China.

Cell Death & Disease
|February 22, 2020
PubMed

Insights

Myotubularin-related protein 14 (MTMR14) protects against cardiac hypertrophy (CH). MTMR14 deficiency worsens CH, while its overexpression prevents it, suggesting MTMR14 as a therapeutic target for heart disease.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Cellular Biology

Background:

  • Cardiac hypertrophy (CH) is a significant risk factor for cardiovascular diseases and mortality, particularly in the elderly.
  • Pathological CH is characterized by excessive protein synthesis, cardiomyocyte enlargement, and progression to heart failure.
  • Myotubularin-related protein 14 (MTMR14) is implicated in cellular processes like apoptosis and autophagy, but its role in CH remains undefined.

Purpose of the Study:

  • To elucidate the function of Myotubularin-related protein 14 (MTMR14) in the context of cardiac hypertrophy (CH).
  • To determine the therapeutic potential of targeting MTMR14 for CH treatment.

Main Methods:

  • Investigated MTMR14 expression levels in hypertrophic mouse hearts.
  • Utilized a mouse model of aortic banding (AB) to induce pressure overload and cardiac hypertrophy.
  • Examined the effects of MTMR14 deficiency and overexpression on the CH phenotype.
  • Analyzed molecular changes, including Akt pathway activation, in response to MTMR14 modulation.

Main Results:

  • MTMR14 expression was found to be upregulated in mouse hearts with cardiac hypertrophy.
  • Mice lacking heart MTMR14 showed exacerbated AB-induced CH.
  • Overexpression of MTMR14 attenuated pressure overload-induced cardiac hypertrophy.
  • Absence of MTMR14 led to increased Akt pathway signaling, which regulates apoptosis and cell proliferation.

Conclusions:

  • MTMR14 plays a protective role in mitigating cardiac hypertrophy.
  • MTMR14 deficiency exacerbates cardiac hypertrophy, while its presence prevents it.
  • MTMR14 represents a novel molecular target for the therapeutic intervention of cardiac hypertrophy and related cardiovascular diseases.

More Related Videos

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes07:32

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes

Published on: May 25, 2022

1.7K
Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

25.3K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
299
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.3K
Structure of Cardiac Muscles01:13

Structure of Cardiac Muscles

Cardiac muscle, or myocardium, is a specialized type of muscle found exclusively in the heart. Its unique structural and functional characteristics enable the heart to perform its vital role of pumping blood throughout the body continuously and rhythmically. The cardiac muscle cells, or cardiomyocytes, possess an endomysium and perimysium but do not have an epimysium.
Compared to skeletal muscles, cardiac muscle cells are small and mostly have a single nucleus. Additionally, they are usually...
16.4K